<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="366279">
  <stage>Registered</stage>
  <submitdate>7/05/2014</submitdate>
  <approvaldate>3/06/2014</approvaldate>
  <actrnumber>ACTRN12614000587606</actrnumber>
  <trial_identification>
    <studytitle>Plasma ropivacaine concentrations and duration of sensory block after ultrasound-guided transversus abdominis plane block, with and without additives (adrenaline and clonidine), for gynaecological surgery</studytitle>
    <scientifictitle>Plasma ropivacaine levels and duration of sensory block in women undergoing gynaecological surgery and having ultrasound-guided transversus abdominis blocks with ropivacaine and additives (clonidine and adrenaline) vs ropivacaine alone</scientifictitle>
    <utrn>U1111-1156-5247</utrn>
    <trialacronym />
    <secondaryid>nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Post operative pain</healthcondition>
    <conditioncode>
      <conditioncode1>Anaesthesiology</conditioncode1>
      <conditioncode2>Pain management</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Ultrasound-guided transversus abdominis plane blocks using either: 
- Ropivacaine 3mg/kg with 1:400,000 adrenaline
- Ropivacaine 3mg/kg with clonidine 2mcg/kg
- Ropivacaine 3mg/kg plus clonidine 2mcg/kg subcutaneous</interventions>
    <comparator>Transversus abdominis plane blocks using:
- Ropivacaine 3mg/kg</comparator>
    <control>Active</control>
    <interventioncode>Treatment: Drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Plasma ropivacaine levels as measured by Gas Chromatograph Mass Spectrometry  following transversus abdominis plane block</outcome>
      <timepoint>Time points following transversus abdominis plane block: every 10 minutes for the first hour, then every 30 minutes until 3 hours post block, and then at 6, 9, and 12 hours post block</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Sensory testing (warm, cold, and Von Frey Filament testing)</outcome>
      <timepoint>3, 6, 9, and 12 hours post block</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Adult female patients, aged 18 to 65, undergoing elective gynaecological surgery and who are planned to receive TAP blocks </inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>65</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Allergy to any of the drugs in the study, morbid obesity, infection at site of block placement, pre-existing neurological or muscular disease, coagulopathy, significant liver or renal disease, and pregnancy.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Sealed opaque envelopes</concealment>
    <sequence>Random number generator called "Research Randomizer"</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Pharmacokinetics / pharmacodynamics</endpoint>
    <statisticalmethods>The total sample size will be 80, with 20 patients allocated to each trial group.  This is effectively a pilot study since there are no studies available that specifically measure blood levels after ropivacaine TAP block with and without clonidine in the literature on which to base a sample size calculation.  However, using the data from the recent study measuring ropivacaine levels in the blood with and without adrenaline (control mean peak level = 2.11mcg/ml +/- 0.31; mean reduction with adrenaline of 13%), we calculate (assuming an estimated effect of clonidine to be 2/3 of that of adrenaline, and with alpha=0.05 and power=0.8), that 17 patients per group will be required.  To allow for potential drop-outs, we will recruit 20 patients per group.

The data will be summarised using appropriate measures of central tendency and tested for normality of distribution.  For parametric data, t-tests and ANOVA will be used.  For non-parametric data, Mann-Whitney U tests or Kruskall-Wallis tests will be used as appropriate.
</statisticalmethods>
    <masking1>True</masking1>
    <masking2>False</masking2>
    <masking3>True</masking3>
    <masking4>True</masking4>
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate>2/06/2014</anticipatedstartdate>
    <actualstartdate>2/06/2014</actualstartdate>
    <anticipatedenddate>30/05/2016</anticipatedenddate>
    <actualenddate />
    <samplesize>80</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW</recruitmentstate>
    <hospital>Royal Prince Alfred Hospital - Camperdown</hospital>
    <postcode>2050 - Missenden Road</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>Royal Prince Alfred Hospital, Sydney Local Health District</primarysponsorname>
    <primarysponsoraddress>Missenden Road,
Camperdown,
2050
NSW</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Hospital</fundingtype>
      <fundingname>Department of Anaesthetics,
Royal Prince Alfred Hospital</fundingname>
      <fundingaddress>Missenden Road,
Camperdown,
2050
NSW</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to assess how clonidine as an additive to local anaesthetics works when used for abdominal wall pain blocks (transversus abdominis plane blocks) after gynaecological surgery.  One hypothesis is that it causes blood vessel constriction and slows the washout of local anaesthetic into the blood stream, therefore leaving it at its site of action for longer.  We will assess this by measuring the levels of local anaesthetic in the blood over time.  Simultaneously, we will assess the abdominal wall sensation to determine if and by how long clonidine improves the duration of postoperative pain relief in these patients.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>SLHD Ethics Review Committee (RPAH Zone)</ethicname>
      <ethicaddress>Research Development Office, RPAH
Missenden Rd, Camperdown, NSW
2050</ethicaddress>
      <ethicapprovaldate>11/04/2014</ethicapprovaldate>
      <hrec>HREC/14/RPAH/10</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>Jennifer Crawford</name>
      <address>Royal Prince Alfred Hospital
Department of Anaesthetics
Missenden Rd, Camperdown
2050
NSW</address>
      <phone>+61 2 95158564</phone>
      <fax />
      <email>jcrawford777@hotmail.com</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Jennifer Crawford</name>
      <address>Royal Prince Alfred Hospital
Department of Anaesthetics
Missenden Rd, Camperdown
2050
NSW</address>
      <phone>+61 2 95158564</phone>
      <fax />
      <email>jcrawford777@hotmail.com</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Jennifer Crawford</name>
      <address>Royal Prince Alfred Hospital
Department of Anaesthetics
Missenden Rd, Camperdown
2050
NSW</address>
      <phone>+61 2 95158564</phone>
      <fax />
      <email>jcrawford777@hotmail.com</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Jennifer Crawford</name>
      <address>Royal Prince Alfred Hospital
Department of Anaesthetics
Missenden Rd, Camperdown
2050</address>
      <phone>61295158564</phone>
      <fax />
      <email>jcrawford777@hotmail.com</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>